Atebimetinib shows promise in enhancing pancreatic cancer treatment, achieving a 64% survival rate and improving patient quality of life.
Igor Matushansky, MD, PhD
Advertisement
Articles by Igor Matushansky, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
CMS Announces 15 Drugs for Third Cycle of Medicare Drug Price Negotiation Program
2
New 2025 Hypertension Management Guidelines Include Key Updates
3
Dextromethorphan Emerges as a Novel Antidepressant Pathway for Treatment-Resistant Depression
4
Pharmacists Key to Rapid Plozasiran Implementation at Stony Brook
5